Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

Université de Montréal

$60,173.00

Collaborative Research Program in Pharmacometrics and Quantitative Systems Pharmacology

EF 2020-21

Résumé
Interdisciplinary initiatives have been identified as a crucial way to synergize research in the modern era, where the complexity of encountered problematics and questions can rarely be solved through in silo efforts. Moreover, because of the big demand for funds and the societal pressure for reporting on return on investments, innovative solutions are increasingly being driven by needs, whether in fundamental or applied sciences. Transcending boundaries between disciplines is thus becoming a necessity rather than a researcher's whim, especially when it comes to human health issues, where discipline-specific projects can often lack vision and scope. The pharmaceutical field is no exception to this change in the research model, motivated by the underlying complexity of the dose-exposure-effect relationship, further challenged by the pathophysiological aspects involved. The empirical culture, which historically prevailed in this field, is gradually fading to give more ground to complementary or alternative mathematical and computational tools, to rationalize and quantify drug development and use. However, the shortage for experienced drug development scientists in quantitative pharmacology/pharmacometrics, with the multi-facets that this field asks for, is a main limiting factor for its deployment in the pharmaceutical industry. With the objective to provide insights into unmeasured or unmeasurable clinical entities, this collaborative research and development (CRD) program is in reflection of this ever-changing nature in drug R&D, and bases on solid theoretical foundations to provide quantification methodologies that support rational therapeutic decisions for improvement of patient health. It is built on well- identified needs in drug R&D where mathematically founded approaches have significant impact and bring added-value. It encompasses several therapeutic areas, including neurological conditions, oncology and infectious diseases. To ensure transferability to the end-users and society, this research program is organically structured to involve translational aspects, through development of computational and mobile health applications that reflect clinical needs. It is dedicated to train a whole generation of drug modelers.
Programme
Collaborative Research and Development Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
539271-2019
Name nom
Nekka, Fahima
Department département
Pharmacie, faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
60173
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
2957
Research subject group en
Applied mathematics
Research subject group fr
Mathématiques appliquées
Research subject en
Mathematical biology andphysiology
Research subject fr
Mathématiques de la biologie et de la physiologie
Installment
inst:2 - 2
Partie
1
Nb partie
2
Application title
Collaborative Research Program in Pharmacometrics and Quantitative Systems Pharmacology
Keyword
NSERC
Application summary
Interdisciplinary initiatives have been identified as a crucial way to synergize research in the modern era, where the complexity of encountered problematics and questions can rarely be solved through in silo efforts. Moreover, because of the big demand for funds and the societal pressure for reporting on return on investments, innovative solutions are increasingly being driven by needs, whether in fundamental or applied sciences. Transcending boundaries between disciplines is thus becoming a necessity rather than a researcher's whim, especially when it comes to human health issues, where discipline-specific projects can often lack vision and scope. The pharmaceutical field is no exception to this change in the research model, motivated by the underlying complexity of the dose-exposure-effect relationship, further challenged by the pathophysiological aspects involved. The empirical culture, which historically prevailed in this field, is gradually fading to give more ground to complementary or alternative mathematical and computational tools, to rationalize and quantify drug development and use. However, the shortage for experienced drug development scientists in quantitative pharmacology/pharmacometrics, with the multi-facets that this field asks for, is a main limiting factor for its deployment in the pharmaceutical industry. With the objective to provide insights into unmeasured or unmeasurable clinical entities, this collaborative research and development (CRD) program is in reflection of this ever-changing nature in drug R&D, and bases on solid theoretical foundations to provide quantification methodologies that support rational therapeutic decisions for improvement of patient health. It is built on well- identified needs in drug R&D where mathematically founded approaches have significant impact and bring added-value. It encompasses several therapeutic areas, including neurological conditions, oncology and infectious diseases. To ensure transferability to the end-users and society, this research program is organically structured to involve translational aspects, through development of computational and mobile health applications that reflect clinical needs. It is dedicated to train a whole generation of drug modelers.
Université de Montréal - $60,173 Grant (2020-21) | Canada Spends